Immunotherapy has emerged as a major therapeutic modality in oncology. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. These therapeutics help the host immune system recognize cancer as foreign, promote the immune system, and relieve the inhibition that allows growth and spread of tumors.
Despite advancements in the treatment of hematological malignancies, solid tumors still represent a challenge. The majority of patients with cancer do not derive benefit from these treatments. Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. These underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer.
The recent clinical successes of immune checkpoint blockade therapies represent a turning point in immunotherapy. In addition, other immunotherapeutic treatments, such as vaccines, antibody-based targeted therapies, and adoptive therapies, are being investigated to treat solid tumors.
This entries collection intends to present insights into the novel approaches in immunotherapy and discuss existing and emerging immunotherapy technologies that hope to translate the promise of immunotherapy for the treatment of solid tumors into clinical reality.